Learn more about a topical calcineurin inhibitor for atopic dermatitis from dermatologist Dr. Cathryn Sibbald
Eczema Society of Canada asked Toronto-based dermatologist Cathryn Sibbald, MD, MSc, FRCPC, DABD, to share her expertise on the topical calcineurin inhibitor Elidel® (pimecrolimus) and how this medication is used to manage atopic dermatitis (AD), commonly known as eczema.
What are topical calcineurin inhibitors?
Topical calcineurin inhibitors are medications that help control the inflammation of AD. They are non-steroidal, meaning they do not contain corticosteroids. Elidel® (pimecrolimus) cream is one of the topical calcineurin inhibitors available in Canada.
How does Elidel® work?
AD flares occur due to an inflammatory response in the skin, and the immune system plays a role in this inflammation. Elidel® can help control flares of AD and work by decreasing AD flares in the skin.
Who is Elidel® approved for?
Elidel® is approved by Health Canada to treat mild to moderate AD in patients 3 months of age and older. It is available in one strength of 1%.
How is Elidel® used?
Elidel® is a cream that is applied directly to the skin. It is typically applied to the skin two times daily (about 12 hours apart) during the periods of flare until the skin improves. However, patients should use this medication exactly as prescribed by their health care provider.1
Will this medication sting or burn my skin?
Uncommonly, users may report a feeling of burning or a sensation of warmth for a few minutes when Elidel® is first applied. For some people, this only occurs for the first few days of use, so if you can, it is best to keep applying the cream regularly, as if you stop and start, the burning sensation can last longer. Speak with your prescribing health care provider about how to use your topical treatments.
What are the side effects of this medication?
Possible side effects include skin irritation, such as burning, stinging, itching, and redness at the site where the medication is applied. All medications have risks and benefits, and the details of the risks and benefits should be reviewed with the prescribing health care provider. If you or your child are experiencing side effects or have any concerns about the treatment, consult your prescribing health care provider.
What if my atopic dermatitis does not get better?
If you find your AD isn’t responding to treatment, let your doctor know, as your treatment plan may need to be adjusted. A qualified health care professional, such as a dermatologist, can help reassess your or your child’s condition and can potentially adjust the treatment plan. There is no cure for AD, but there are now many treatments that can help patients.
Eczema Society of Canada thanks Cathryn Sibbald, MD, MSc, FRCPC, DABD, for her volunteer contribution to this educational content.
Reference: 1 Bausch Health, Canada Inc. (Date of Revision January 2020). Elidel® (pimecrolimus) [Product Monograph], Topical Calcineurin Inhibitor.
Disclaimer: Information provided in this resource does not constitute medical advice and is not intended to be used as a diagnostic tool. The information is up-to-date at time of publication. All medications, interventions, and treatment plans have risks and benefits, and it is important that individuals discuss their or their child’s specific health care needs with a qualified health care professional.
